These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30661162)

  • 1. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Holstein SA; Suman VJ; McCarthy PL
    Curr Hematol Malig Rep; 2019 Feb; 14(1):31-38. PubMed ID: 30661162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
    Pawlyn C; Schjesvold FH; Cairns DA; Wei LJ; Davies F; Nadeem O; Abdulhaq H; Mateos MV; Laubach J; Weisel K; Ludwig H; Rajkumar SV; Sonneveld P; Jackson G; Morgan G; Richardson PG
    Blood Cancer J; 2024 Aug; 14(1):134. PubMed ID: 39134544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
    Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
    Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
    Dimopoulos M; Sonneveld P; Manier S; Lam A; Roccia T; Schecter JM; Cost P; Pacaud L; Poirier A; Tremblay G; Lan T; Valluri S; Kumar S
    BMC Cancer; 2024 Apr; 24(1):541. PubMed ID: 38684948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
    Pilz LR; Manegold C; Schmid-Bindert G
    Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib for the treatment of multiple myeloma.
    Scott K; Hayden PJ; Will A; Wheatley K; Coyne I
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010816. PubMed ID: 27096326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari S; Hillengass J; McCarthy PL; Holstein SA
    Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
    Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
    BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
    Etekal T; Koehn K; Sborov DW; McClune B; Prasad V; Haslam A; Berger K; Booth C; Al Hadidi S; Abdallah AO; Goodman A; Mohyuddin GR
    Br J Haematol; 2023 Mar; 200(5):587-594. PubMed ID: 36495317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint.
    Rosenberg AS; Facon T; Parikh K; Chung W; Srinivasan S; Kotey S; Tuscano J
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):345-354.e4. PubMed ID: 33563582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
    Front Oncol; 2022; 12():810580. PubMed ID: 35155246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
    Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
    Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.
    Cartier S; Zhang B; Rosen VM; Zarotsky V; Bartlett JB; Mukhopadhyay P; Wagner S; Davis C
    Oncol Res Treat; 2015; 38(3):88-94. PubMed ID: 25792079
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.